Related Experiment Video
Updated: Feb 3, 2026

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules
Published on: October 4, 2024
A Novel Engineered Small Protein for Positron Emission Tomography Imaging of Human Programmed Death Ligand-1:
Arutselvan Natarajan1, Chirag B Patel1,2, Sindhuja Ramakrishnan1
1Molecular Imaging Program at Stanford (MIPS), Department of Radiology, Stanford University, Stanford, California.
Purpose:
To design and evaluate a small engineered protein binder targeting human programmed death-1 ligand (hPD-L1) in vivo for PET imaging in four mouse tumor models, and in situ in human cancer specimens.Experimental Design: The hPD-L1 protein binder, FN3hPD-L1, was engineered using a 12-kDa human fibronectin type-3 domain (FN3) scaffold. The binder's affinity was assayed in CT26 mouse colon carcinoma cells stably expressing hPD-L1 (CT26/hPD-L1). 64Cu-FN3hPD-L1 was assayed for purity, specific activity, and immunoreactivity. Four groups of NSG mice (n = 3-5/group) were imaged with 64Cu-FN3hPD-L1 PET imaging (1-24 hours postinjection of 3.7 MBq/7 μg of Do-FN3 in 200 μL PBS): Nod SCID Gamma (NSG) mice bearing (i) syngeneic CT26/hPD-L1tumors, (ii) CT26/hPD-L1 tumors blocked (blk) by preinjected nonradioactive FN3hPD-L1 binder, (iii) hPD-L1-negative Raji xenografts, and (iv) MDA-MB-231 xenografts. The FN3hPD-L1 binder staining was evaluated against validated hPD-L1 antibodies by immunostaining in human cancer specimens.
Results:
FN3hPD-L1 bound hPD-L1 with 1.4 ± 0.3 nmol/L affinity in CT26/hPD-L1 cells. 64Cu-FN3hPD-L1 radiotracer showed >70% yield and >95% purity. 64Cu-FN3hPD-L1 PET imaging of mice bearing CT26/hPD-L1 tumors showed tumor-to-muscle ratios of 5.6 ± 0.9 and 13.1 ± 2.3 at 1 and 4 hours postinjection, respectively. The FN3hPD-L1 binder detected hPD-L1 expression in human tissues with known hPD-L1 expression status based on two validated antibodies.
Conclusions:
The 64Cu-FN3hPD-L1 radiotracer represents a novel, small, and high-affinity binder for imaging hPD-L1 in tumors. Our data support further exploration and clinical translation of this binder for noninvasive identification of cancer patients who may respond to immune checkpoint blockade therapies.
Insights
A novel small protein binder, 64Cu-FN3hPD-L1, effectively images human programmed death-1 ligand (hPD-L1) in tumors using PET. This tracer shows promise for identifying cancer patients eligible for immune checkpoint therapies.
Area of Science:
- Biotechnology
- Molecular Imaging
- Oncology
Background:
- Immune checkpoint blockade therapies, such as those targeting human programmed death-1 ligand (hPD-L1), have revolutionized cancer treatment.
- Accurate identification of patients who will respond to these therapies is crucial for optimizing treatment outcomes.
- Current imaging methods for hPD-L1 expression have limitations, necessitating the development of novel, high-affinity tracers.
Purpose of the Study:
- To design and evaluate a small engineered protein binder, FN3hPD-L1, for targeting hPD-L1.
- To assess the in vivo performance of the radiolabeled binder (64Cu-FN3hPD-L1) using Positron Emission Tomography (PET) imaging in mouse tumor models.
- To evaluate the binder's utility for in situ imaging in human cancer specimens.
Main Methods:
- Engineered a 12-kDa human fibronectin type-3 domain (FN3) scaffold to create the FN3hPD-L1 binder.
- Assayed binder affinity using CT26 mouse colon carcinoma cells expressing hPD-L1 (CT26/hPD-L1).
- Radiolabeled FN3hPD-L1 with Copper-64 (64Cu) and evaluated the resulting tracer (64Cu-FN3hPD-L1) for purity, specific activity, and immunoreactivity.
- Conducted PET imaging in NSG mice bearing various tumors (hPD-L1-positive syngeneic, hPD-L1-negative xenografts, and hPD-L1-positive xenografts with blocking) and evaluated immunostaining in human cancer specimens.
Main Results:
- FN3hPD-L1 demonstrated high affinity (1.4 ± 0.3 nmol/L) for hPD-L1.
- The 64Cu-FN3hPD-L1 radiotracer exhibited high yield (>70%) and purity (>95%).
- PET imaging revealed significant tumor uptake in mice with CT26/hPD-L1 tumors, with tumor-to-muscle ratios of 5.6 ± 0.9 at 1 hour and 13.1 ± 2.3 at 4 hours postinjection.
- The binder successfully detected hPD-L1 expression in human tissues, correlating with validated antibody staining.
Conclusions:
- The 64Cu-FN3hPD-L1 radiotracer is a novel, small, high-affinity binder suitable for imaging hPD-L1 in tumors.
- The findings support the potential clinical translation of this binder for noninvasive identification of cancer patients who may benefit from immune checkpoint blockade therapies.
More Related Videos
09:5718F-Labeling of Radiotracers Functionalized with a Silicon Fluoride Acceptor SiFA for Positron Emission Tomography
Published on: January 11, 2020
09:21Human Brown Adipose Tissue Depots Automatically Segmented by Positron Emission Tomography/Computed Tomography and Registered Magnetic Resonance Images
Published on: February 18, 2015
Related Concept Videos
Positron Emission Tomography
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
Imaging Studies II: Positron Emission Tomography and Scintigraphy
Fundamental Principles of PET
Role of Proteins in the Human Body
Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
Ligand Binding Sites
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Emission Spectra